USU Home A-Z index calendars MyUSU contact people/web search
 

Department of Animal, Dairy and Veterinary Sciences
 

Donald Smee

Donald F. Smee, PhD
 Research Professor
Institute for Antiviral Research

Utah State University
ADVS Department
5600 Old Main Hill
Logan UT 84322-5600

phone (435)797-2897
fax (435)797-3959
email dsmee at cc.usu.edu

 

  
 
PRESENTATIONS AT SCIENTIFIC MEETINGS
 
  1. Smee, D.F., A.C. Morrison, K.W. Bailey, and R.W. Sidwell, 2001. Efficacy of 2-amino-7-(1,3-dihydroxy- 2-propoxymethyl)purine(S2242) and its orally active prodrug (HOE961) for the treatment of lethal cowpox virus respiratory infections in mice. Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C., p. 301.


  2. Morrey, J.D., Smee, D.F., and R.W. Sidwell, 2001. In vitro evaluation of compounds against West Nile virus. Antiviral Res. 50:A70.


  3. Smee, D.F., K.W. Bailey, and R.W. Sidwell, 2001. Vaccinia virus respiratory infection model in mice for antiviral studies. Antiviral Res. 50:A69.


  4. Sidwell, R.W., K.W. Bailey, A. Morrison, and Smee, D.F., 2000. Failure of in vivo development of influenza A resistance to the orally administered neuraminidases inhibitor RWJ-270201. III International Symposium on Respiratory Viral Infections. St. Lucia, West Indies.


  5. Smee, D.F., K.W. Bailey, A. Morrison, and R.W. Sidwell, 2000. Combination treatment of an influenza A/NWS/33 (H1N1) virus infection in mice with neuraminidase inhibitor RWJ-270201 and ribavirin. III International Symposium on Respiratory Viral Infections. St. Lucia, West Indies.


  6. Sidwell, R.W., Smee, D.F., J.D. Morrey, K.W. Bailey, and K. Bush, 2000. The influenza virus neuraminidase inhibitor RWJ-270201: immunological effects and inhibition of influenzal disease in the immunocompromised host. Options for the Control of Influenza IV. Hersonissos, Crete, Greece.


  7. Smee, D.F., R.W. Sidwell, A.C. Morrison, K.W. Bailey, S. Bantia, and P.C. Wagaman, 2000. Influenza virus resistance to the neuraminidase inhibitor RWJ-270201 is due to a single point mutation in the hemagglutinin protein and results in decreased virulence in mice. Options for the Control of Influenza IV. Hersonissos, Crete, Greece.


  8. Smee, D.F., R.W. Sidwell, A.C. Morrison, K.W. Bailey, P.C. Wagaman, and S. Bantia, 2000. Influenza A viruses resistant to the neuraminidase inhibitor RWJ-270201 exhibit reduced virulence in mice. Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C., p. 271.


  9. Sidwell, R.W., Smee, D.F., J.D. Morrey, K.W. Bailey, and K. Bush, 2000. Effect of oral treatment with theneuraminidase inhibitor RWJ-270201 on influenza virus infections in immunosuppressed mice. 11th International Symposium on Infections in the Immunocompromised Host. Halifax, Nova Scotia, Canada.


  10. Wong, M.-H., D.L. Barnard, M.K. Jackson, Smee, D.F., R.A. Burger, and R.W. Sidwell, 2000. Utilization of Alpha 1-acid glycoprotein levels in the serum as a parameter for in vivo assay of influenza virus inhibitors. Antiviral Res. 46:A61.


  11. Sidwell, R.W., Smee, D.F., K.W. Bailey, J.H. Huffman, D.L. Barnard, M.-H. Wong, K. Bush, and Y.S. Babu, 2000. In vivo influenza-inhibitory effects of the orally administered cyclopentane neuraminidase inhibitor RWJ-270201. Antiviral Res. 46:A54.


  12. Smee, D.F., A.C. Morrison, J.H. Huffman, D.L. Barnard, P.C. Wagaman, K. Bush, and R.W. Sidwell, 2000. A new class of cyclopentane derivatives with potent inhibitory activity against influenza A and B viruses in cell culture. Antiviral Res. 46:A53.


  13. Zaveri, N., W.W. Bradford, E. Reist, Smee, D.F., J.H. Huffman, and R.W. Sidwell, 2000. Enantiomerically pure 2-aminopurine cyclic and acylic nucleotide phosphonate analogs as antiviral agents against human cytomegalovirus. 219th American Chemical Society National Meeting. San Francisco, California.


  14. Zaveri, N., M.J. Tanga, W.W. Bradford, E. Reist, Smee, D.F., J.H. Huffman, and R.W. Sidwell, 2000. Benzthieno[3,2-h]isoquinolines as novel nonnucleoside inhibitors of human cytomegalovirus. 219th American Chemical Society National Meeting. San Francisco, California.


  15. Smee, D.F. and J.W. Huggins, 1999. Mode of action of ribavirin against cowpox and monkeypox viruses. Antiviral Res. 41:A52.


  16. Huggins, J.W., M.J. Martinez, G.M. Zaucha, P.B. Jahrling, Smee, D.F., and M. Bray, 1998. The DNA polymerase inhibitor cidofovir (HPMPC, VistideTM) is a potential antiviral therapeutic agent for the treatment of monkeypox and other orthopoxvirus infections. Twelfth International Poxvirus Symposium. St. Thomas, U.S. Virgin Islands.


  17. Smee, D.F. and J.W. Huggins, 1998. Potential of the IMP dehydrogenase inhibitors for antiviral therapies of poxvirus infections. Antiviral Res. 37:A89.


  18. Huggins, J.W., Smee, D.F., M.J. Martinez, and M. Bray, 1998. Cidofovir (HPMPC) treatment of monkeypox. Antiviral Res. 37:A73.


  19. Tatti, K.M., H. Stang, D. Barnard, Smee, D.F., and R.F. Schinazi, 1998. Mutations occur in highly conserved domains of murine cytomegalovirus DNA polymerase in cidofavir- and lobucavir-resistant strains. Antiviral Res. 37:A70.


  20. Huggins, J.W., Smee, D.F., and M. Bray, 1998. The DNA polymerase inhibitor cidofovir (HPMPC) is a potential antiviral theratuetic agent for the treatment of monkeypox. International Conference on Emerging Infectious Diseases. Atlantic, Georia.


  21. Smee, D.F., K.W. Bailey, and R.W. Sidwell, 1997. Evaluation of potential treatments for Epstein-Barr virus infections in man using a murine gammaherpesvirus-68 infection model. Antiviral Res. 34:A71.


  22. Spruance, S.L., M. McKeough, I. Yanachkov, G.E. Wright, E. Kern, R. Sidwell, Smee, D.F., M. Yanachkova, and A. Glazier, 1996. The design, chemistry, and antiviral activity of a novel group of anti-herpes prodrugs. Antiviral Res. 30:A44.


  23. Smee, D.F., 1996. Drug combination studies in vitro and in immunosuppressed mice: exploring ways to overcome or prolong the emergence of CMV drug resistance. International Consensus Symposium on Advances in the Diagnosis, Treatment and Prophylaxis of CMV Infection. Fort Myers, Florida.


  24. Ainso, S., A. Glanville, Smee, D.F., K. Zilmer, M. Raukas, and V. Ustina, 1995. Solutein's strong immunomodulatory effects in HIV-infected patients: results of a clinical trial in Estonia. Fifth European Conference on Clinical Aspects and Treatment of HIV Infection. Copenhagen, Denmark.


  25. Smee, D.F., A. Glanville, D.R. Warden, S. Ainso, K. Zilmer, M. Raukas, and V. Ustina, 1995. Efficacy of Solutein in treating HIV disease in Estonia. Can. J. Infect. Dis. 6(Suppl. C):367C.


  26. Smee, D.F. and E.J. Reist, 1995. Murine cytomegalovirus (MCMV) resistance to antiviral drugs. Can. J. Infect. Dis. 6(Suppl. C):288C.


  27. Smee, D.F. and Verbiscar, A.J, 1995. Plant polysaccharide antiviral agents from Astragalus and Sterculia species. Antiviral Res. 26:A353.


  28. Smee, D.F., K.M. Okleberry, B.B. Barnett, and R.W. Sidwell, 1995. Activities of antimurine cytomegalovirus (MCMV) immunotoxins used alone or in combination with antiviral agents against MCMV infections. Antiviral Res. 26:A323.


  29. Barnett, B.B., Smee, D.F., and R.W. Sidwell. 1995. Selective elimination of cytomegalovirus infected cells by immunotoxins targeted with various antibodies linked to ricin A chain or gelonin. Antiviral Res. 26:A323.


  30. Revankar, G.R., T.S. Rao, K. Ramasamy, and Smee, D.F., 1994. Synthesis and broad-spectrum antiviral activity in mice of certain alkyl, alkenyl and ribofuranosyl derivatives of 7-deozaguanine. Eleventh International Round Table on Nuclosides, Nucleotides and Their Biological Applications. Leuven, Belgium.


  31. Smee, D.F., S.T. Sugiyama, and J.A. Leonhardt, 1994. Vaccination and therapy of bovine herpes mammillitis virus infections. Abstracts of the 94th General Meeting of the American Society for Microbiology, Washington, D.C., p. 482.


  32. Hansen, L.J., J.W. Lillie, Smee, D.F., J.H. Huffman, R.W. Sidwell, and R. Kaddurah-Daouk, 1994. Cyclocreatine (1-carboxymethyl-2-iminoimidazolidine) inhibits the replication of human herpes viruses. Antiviral Res. 23 (Suppl.1):135.


  33. Smee, D.F., S.T. Sugiyama, R.W. Sidwell, and B.B. Barnett, 1994. Treatment of murine cytomegalovirus (MCMV) infections in cell culture and in immunocompromised mice using antibodies to MCMV alone and in combination with ganciclovir (GCV) or (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC). Antiviral Res. 23 (Suppl. 1):106.


  34. Smee, D.F., S.T. Sugiyama, J.H. Huffman, N. Zaveri and E.J. Reist, 1994. Phosphonate derivatives of ganiciclovir and acyclovir inhibit murine cytomegalovirus (MCMV) infections in cell culture and in mice. Antiviral Res. 23 (Suppl.1):42.


  35. Smee, D.F., R.W. Sidwell, and E.J. Reist, 1993. Sensitivities of nucleosides and nuclotides to drug-resistant strains of murine cytomegalovirus (MCMV). Program and Abstracts of the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C., p. 402.


  36. Smee, D.F., J.K. Yamamoto, D.R. Warden, J.C. Diaz, and A. Glanville, 1993. Solutein treatment of HIV infected patients. Abstracts of the IXth International Conference on AIDS. Berlin, Germany, p. 492.


  37. Bischofberger, N., E. Prisbe, M. Arimilli, K. Cundy, B. Lee, and Smee, D.F., 1993. Evaluation of nucleotide prodrugs as inhibitors of viral replication. Antiviral Res. 20 (Suppl.1):142.


  38. Smee, D.F. and J.A. Leonhardt, 1993. Bovine herpes mammillitis virus inhibitors in vitro and in a novel guinea pig vaginal infection model. Antiviral Res. 20(Suppl. 1):126.


  39. Smee, D.F., J.K. Yamamoto, D.R. Warden, J.C. Diaz, and A. Glanville, 1993. Improvement of health status of HIV infected individual treated with Solutein. Antiviral Res. 20(Suppl. 1):88.


  40. Smee, D.F., 1993. Sensitivities of drug-resistant strains of murine cytomegalovirus to antiviral agents. Fourth International Cytomegalovirus Conference: Multidisciplinary Approach to Understanding Cytomegalovirus Disease. Paris, France.


  41. Sidwell, R.W., Smee, D.F., J.H. Huffman, R.P. Warren, R.A. Burger, and C.L. Penney, 1993. Inhibitition of murine cytomegalovirus infections by an immunomodulatory lipophilic desmuramyl MDP analog. Fourth International Cytomegalovirus Conference: Multidisciplinary Approach to Understanding Cytomegalovirus Disease. Paris, France.


  42. Smee, D.F. and J.L. Leonhardt, 1993. Vaccine adjuvant potential of immunostimulatory nucleoside analogs in different animal species. Second International Congress on Biological Response Modifiers, San Diego, California.


  43. Gabrielsen, B., T.P. Monath,J.T. Rankin, J.W. Huggins, D.F. Defauver, C.D. Kwong, C.A. Krauth, J.A. Secrist III, J.H. Huffman, Smee, D.F., and R.W. Sidwell, 1992. Synthesis and in vivo anti-RNA-viral evaluation of phosphoramidate derivative of 6-azauridine; orotidylic acid decarboxylas inhibitors, pyrazofurin and 6-azauridine; and 2-thio-6-azauridine and its triacetate. Antiviral Res. 17(Suppl.1):149.


  44. Smee, D.F., J.L.B. Morris, J.R. Mead, and R.W. Sidwell, 1992. The SCID mouse model for evaluation of antiviral agents against murine cytomegalovirus. Antiviral Res. 17(Suppl.1):124.


  45. Smee, D.F., J. Coombs, R.A. Burger, J.H. Huffman, K.M. Okleberry, J.D. Morrey, and R.W. Sidwell, 1991. New models of murine cytomegalovirus infection in immunocompromised mice. Antiviral Res. 15(Suppl.1):133.


  46. Smee, D.F., J.L.B. Morris, D.L. Barnard, and A. Van Aerschot, 1991. Selective inhibition of alpha-, arena-, bunya-, and flaviviruses by 3'-fluoro-3'-deoxyadenosine. Antiviral Res. 15(Suppl. 1):63.


  47. Smee, D.F., R.W. Sidwell, G.R. Revankar, H.B. Cottam, and R.K. Robins, 1991. 7-Thia-8-oxoguanosine: a viral disease-inhibiting immunomodulating nucleoside. First International Congress on Biological Response Modifiers. Quebec City, Quebec, Canada.


  48. Sidwell, R.W., J.H. Huffman, Smee, D.F., and M. Kende, 1991. Potential role of immunomodulators for treatment of Phlebovirus infections of animals. First Biennial Meeting of the American Society of Tropical Veterinary Medicine. San Juan, Puerto Rico.


  49. Smee, D.F., J.H. Huffman, J. Coombs, and R.W. Sidwell, 1990. Development of murine cytomegalovirus infections in immunocompromised mice: treatment with ganciclovir. Program and Abstracts of the 30th Interscience on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C., p. 270.


  50. Robins, R.K., Smee, D.F., H.B. Cottam, N. Girgis, A. Alaghamandan, G.R. Revankar, K. Ramasamy, G.D. Kini, and W.B. Jolley, 1990. In vivo antiviral activity of new immunomodulatory guanosine analogs. Fourth International Antiviral Symposium: Clinical, Pharmacological and Basic Aspects. Taipei, Taiwan.


  51. Smee, D.F., J.H. Huffman, J. Coombs, J.W. Huggins, and R.W. Sidwell, 1990. Effects of 7-thia-8-oxoguanosine alone and in combination with ribavirin on Punta Toro virus infections inmice. Antiviral Res. 13(Suppl. 1):120.


  52. Robins, R.K., Smee, D.F., H.A. Alaghamandan, A. Jin, W.B. Jolley, K. Ramasamy, and G.R. Revankar, 1990. 7-Deazaguanosine, a new immune enhancer active against RNA viral infections in mice. Antiviral Res. 13(Suppl. 1):45.


  53. Smee, D.F., M.L. Bartlett, H.A. Alaghamandan, and R.K. Robins, 1990. Animal models for the common cold: treatment with the interferon inducing agent 7-thia-8-oxoguanosine. J. Cell. Biochem. Suppl. 14D:74.


  54. Smee, D.F., H.A. Alaghamandan, A. Jin, and B.S. Sharma, 1989. Roles of interferon and natural killer cells in the antiviral activity of 7-thia-8-oxoguanosine against Semliki Forest virus infections in mice. International Symposium on Antiviral Chemotherapy, Porto Cervo, Sardinia, Italy.


  55. Smee, D.F., H.A. Alaghamandan, B.S. Sharma, W.B. Jolley, H.B. Cottam, and R.K. Robins, 1989. The novel immunopotentiating agent 7-thia-8-oxoguanosine is a broad-spectrum antiviral agent. International Symposium on Antiviral Chemotherapy, Porto Cervo, Sardinia, Italy.


  56. Smee, D.F., H.B. Cottam, H.A. Alaghamandan, and R.K. Robins, 1989. Broad-spectrum in vivo antiviral activity of 7-thia-8-oxoguanosine, a novel immunopotentiating agent. Program and Abstracts of the 29th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C., p. 327.


  57. Smee, D.F., B. Sharma, H.B. Cottam, R.K. Robins, and W.B. Jolley, 1988. Antiviral activity of a novel nucleoside immunopotentiating agent. Second Symposium on Current Problems in Testing and Evaluation of Experimental and Clinical Effects of Immunomodulators, Kosice, Czechoslovakia.


  58. Smee, D.F., H.A. Alaghamandan, G.D. Kini, and R.K. Robins, 1988. Effects and mode of action of ribavirin analog N3844 against Semliki Forest virus. Antiviral Res. 9:97.


  59. Nord, L.D., R.C. Willis, Smee, D.F., T. Riley, G.R. Revankar, and R.K. Robins, 1988. The antiviral nucleoside, allopurinolriboside-3-thiocarboxamide is a potent inhibitor of orotidylate decarboxylase. FASEB J. 2:A1349.


  60. Smee, D.F., A. Colletti, L. Winter, H.A. Alaghamandan, C.R. Petrie, P.A. McKernan, R.C. Willis, L.D. Nord, G.R. Revankar, R.K. Robins, and R.A. Smith, 1987. A novel purine nucleoside analog with broad spectrum anti-DNA and -RNA virus inhibitory activity. Antiviral Drug Development: A Multidisciplinary Approach. NATO Advanced Study Institute, I1 Ciocco, Italy.


  61. Smee, D.F., M. Chernow, R. Boehme, and T.R. Matthews, 1983. Enzymatic phosphorylation and intracellular metabolism of 9-(1,3-dihydroxy-2-propoxymethyl)guanine (DHPG). Program and Abstracts of the 23rd Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C., p. 106.


  62. Fraser-Smith, E.B., Smee, D.F., and T.R. Matthews, 1983. Efficacy of 9-(1,3-dihydroxy-2-propoxymethyl)guanine against primary and recrudescent genital herpes infections in guinea pigs. Program and Abstracts of the 23rd Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C., p. 105.


  63. Smee, D.F., J.C. Martin, J.P.H. Verheyden, and T.R. Matthews, 1983. Comparative anti-herpes virus activity of two acyclic nucleosides: 9-(1,3-dihydroxy-2-propoxy-methyl)guanine and acyclovir. 13th International Congress of Chemotherapy. Vienna, Austria.


  64. Matthews, T.R., Smee, D.F., J.C. martin, and J.P.H. Verheyden, 1983. The potent anti-herpes virus activity of 9-(1,3-dihydroxy-2-propoxymethyl)guanine. Fed Proc. 42(4):457.


  65. Matthews, T.R., B. Binko, R. Boehme, M. Chernow, E. Fraser-Smith, V. Freitas, Smee, D.F., J. Martin, and J. Verheyden, 1983. Comparative anti-herpes virus activity of two acyclic nucleosides: dihydroxypropoxymethlguanine and acyclovir. Conference on Pathogenesis and Prevention of Human Cytomegalovirus Infection. Children's Hospital of Philadelphia, Pennsylvania.


  66. Martin, J.C., G.A. Jeffrey, D.P.C. McGee, M.A. Tippie, Smee, D.F., T.R. Matthews and J.P.H. Verheyden, 1983. Synthesis and antiviral activity of acyclic nucleosides related to DHPG. 185th ACS National Meeting, American Chemical Society, Washington, D.C., p. 43.


  67. Smee, D.F., J.C. Martin, J.P.H. Verheyden, and T.R. Matthews, 1983. 9-(1,3-Dihydroxy-2-propoxymethyl)guanine: an acyclic nucleoside exhibiting potent antiherpes-virus activity. Abstracts of the 83rd Annual Meeting of the American Society for Microbiology, Washington, D.C., p. 290.


  68. Verheyden, J.P.H., J.C. Martin, C.A. Dvorak, T.R. Matthews, Smee, D.F., M.D. Chaplin, S. Kushinski, I.J. Massey, and R.G. Bergstrom, 1982. DHPG: a potent and selective anti-herpes agent. Fifth International Round Table on Nucleosides, Nucleotides and Their Biological Applications. Research Triangle Park, North Carolina.


  69. Martin, J.C., J.P.H. Verheyden, Smee, D.F., and T.R. Matthews, 1982. Synthesis of b-hydroxyketo-analogs of acyclic nucleosides. Fifth International Round Table on Nucleosides, Nucleotides and Their Biological Applications. Research Triangle Park, North Carolina.


  70. Sidwell, R.W., Smee, D.F., and J.H. Huffman, 1981. Influence of vehicle on the in vivo antiherpesvirus 2 (HSV/2) activity of ribavirin. Program and Abstracts of the 21st Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C., p. 874.


  71. Sidwell, R.W., Smee, D.F., S.M. Clark, B.B. Barnett, and R.S. Spendlove, 1981. Inhibition of rotaviruses by selected antiviral substances. Abstracts of the 81st Annual Meeting of the American Society of Microbiology, Washington, D.C., p. 249.


  72. Smee, D.F., R.W. Sidwell, B.B. Barnett and R.S. Spendlove, 1981. Inhibition of bluetongue and Colorado tick fever orbiviruses by selected antiviral substances. Abstracts of the 81st Annual Meeting of the American Society for Microbiology, Washington, D.C., p. 6.


  73. Smee, D.F., R.S. Spendlove, B.B. Barnett, and R.W. Sidwell, 1979. Virus-inhibitory effects of ribavirin in the presence of human serum and urine. Abstracts of the 79th Annual Meeting of the American Society for Microbiology, Washington, D.C., p. 11.